Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SNS-032 Injection
SNS-032 · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| Dose-escalation of SNS-032 injection | EXPERIMENTAL | Patients escalated to MTD starting in Cohort 1 of 15 mg/m2 of SNS-032 injection, with 1.5-fold increase each cohort and a maximum loading dose increase of 10 mg/m2. Each dose cohort will have a minimum of 3 patients each with advanced CLL or MM. Dose escalation continues in the absence of Cycle 1 DLT criteria until an MTD is achieved for each disease type to a maximum of 7 cohorts at a high dose of 70 mg/m2. Stage 2 tests at MTD in larger group. |
| Name | Type | Description |
|---|---|---|
| SNS-032 Injection | DRUG | Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1 |
Inclusion Criteria: * Cytologically or histologically confirmed chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), or multiple myeloma (MM). * Evidence of relapsed disease * Measurable disease * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 Exclusion Cri...
SNS-032 is an investigational small molecule developed by Viracta Therapeutics, Inc. (ticker VIRX). It was studied in Phase 1 clinical trials as an intravenously administered agent for advanced B-lymphoid malignancies and for select advanced solid tumors. It is not an approved therapy and remains in clinical development.
SNS-032 was studied in Phase 1 trials for advanced B-lymphoid malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, and multiple myeloma, as well as for select advanced solid tumors. These were investigational uses in clinical research, not approved indications.
SNS-032 is developed by Viracta Therapeutics, Inc., which trades under the ticker VIRX. The company sponsored the Phase 1 clinical trials of the intravenously administered small molecule in patients with advanced B-lymphoid malignancies and select advanced solid tumors.
SNS-032 is in Phase 1. Both of its clinical trials were Phase 1 studies and both are completed. No later-phase trials are recorded, and the drug is investigational rather than approved.
SNS-032 has been studied in two completed Phase 1 trials. NCT00446342 evaluated intravenous SNS-032 in patients with advanced B-lymphoid malignancies, enrolling 21 patients. NCT00292864 assessed one-hour infusions of SNS-032 in patients with select advanced solid tumors, enrolling 25 patients. Both trials were conducted in the United States.
Yes. SNS-032 Injection is another name for SNS-032, the investigational small molecule developed by Viracta Therapeutics, Inc. (ticker VIRX). The intravenous formulation was the one used in its Phase 1 trials in B-lymphoid malignancies and advanced solid tumors.